| Pathologic Tumor Response of Invasive Lobular Carcinoma to Neo-adjuvant Chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 23034096 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Neo-adjuvant chemotherapy is used for locally advanced breast cancer patients with significant variation in tumor response. Our objective is to determine the clinicopathologic effect of neo-adjuvant chemotherapy on invasive lobular carcinoma. A review of a single-institution data base of women diagnosed with breast cancer identified 30 patients from 1999 to 2009 with operable invasive lobular carcinoma who received neo-adjuvant chemotherapy. Patient demographics and clinicopathologic data were reviewed. Cases were reviewed by a single pathologist (NNE). Residual cancer burden class was determined for each case. Median patient age was 50 years (range 25-79). All tumors were hormone receptor positive and clinical stage II or III carcinomas. Most patients (53.3%) had combination anthracycline- and taxane-based chemotherapy. Therapy-related changes were noted within the tumor bed in 25 (83.3%) patients. Six (30%) of 20 patients with residual axillary disease had therapy-related nodal changes. There were 11 patients with moderate residual disease (class II) and 18 (60%) with extensive (class III); there were no complete pathologic responses (class 0). Only one patient (3.3%) converted from mastectomy to breast-conserving surgery. Four (13.3%) patients developed distant metastases; all had pleomorphic-type, clinical stage III tumors with residual cancer burden III classification and developed distant disease in the 2 years after surgery (range 0-26 months). Median follow-up time was 29.5 months (range 7-132). Patients with locally advanced pleomorphic-type lobular carcinoma appear to develop early post-treatment metastatic disease. Neo-adjuvant chemotherapy did not appear to have significant impact on the surgical treatment of patients with invasive lobular carcinoma. |
| | |
Authors:
|
Jennifer E Joh; Nicole N Esposito; John V Kiluk; Christine Laronga; Nazanin Khakpour; Hatem Soliman; M Catherine Lee |
Related Documents
:
|
17239326 - Prevention of emesis from multiple-day and high-dose chemotherapy regimens. 23304556 - The role of radiotherapy and chemotherapy in the treatment of primary adult high grade ... 12099946 - An analysis of the antiemetic protection of metoclopramide plus dexamethasone in chines... 22956006 - A randomized double-blind placebo-controlled cross-over trial of the impact on quality ... 12057146 - Gastroesophageal junction adenocarcinoma. 16968876 - Is a patient's self-reported health-related quality of life a prognostic factor for sur... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-10-4 |
Journal Detail:
|
Title: The breast journal Volume: - ISSN: 1524-4741 ISO Abbreviation: Breast J Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9505539 Medline TA: Breast J Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2012 Wiley Periodicals, Inc. |
Affiliation:
|
Comprehensive Breast Program, Department of Women's Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida Department of Pathology, University of South Florida, Tampa, Florida. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 'Placement budgets' for supported employment -- improving competitive employment for people with men...
Next Document: Validation of a home food inventory among low-income Spanish- and Somali-speaking families.